Label: CICLOPIROX OLAMINE- ciclopirox olamine cream

  • NDC Code(s): 0713-0638-15, 0713-0638-18, 0713-0638-31
  • Packager: Cosette Pharmaceuticals, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated December 7, 2020

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Ciclopirox Olamine Cream USP, 0.77% is for topical use.
    Each gram of Ciclopirox Olamine Cream USP contains 7.70 mg of ciclopirox (as ciclopirox olamine) in a water miscible vanishing cream base consisting of purified water USP, octyldodecanol NF, mineral oil USP, stearyl alcohol NF, cetyl alcohol NF, cocamide DEA, polysorbate 60 NF, myristyl alcohol NF, sorbitan monostearate NF, lactic acid USP, and benzyl alcohol NF (1%) as preservative.

    Ciclopirox Olamine Cream USP contains a synthetic, broad spectrum, antifungal agent ciclopirox (as ciclopirox olamine). The chemical name is 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, 2-aminoethanol salt.

    The CAS Registry Number is 41621-49-2. The chemical structure is:

    structure

  • CLINICAL PHARMACOLOGY

    Mechanism of Action
    Ciclopirox is a hydroxypyridone antifungal agent that acts by chelation of polyvalent cations (Fe3+ or A13+), resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell.

    Pharmacokinetics
    Pharmacokinetic studies in men with tagged ciclopirox solution in polyethylene glycol 400 showed an average of 1.3% absorption of the dose when it was applied topically to 750 cm2 on the back followed by occlusion for 6 hours. The biological half-life was 1.7 hours and excretion occurred via the kidney. Two days after application only 0.01% of the dose applied could be found in the urine. Fecal excretion was negligible.

    Penetration studies in human cadaverous skin from the back, with Ciclopirox Olamine Cream with tagged ciclopirox showed the presence of 0.8 to 1.6% of the dose in the stratum corneum 1.5 to 6 hours after application. The levels in the dermis were still 10 to 15 times above the minimum inhibitory concentrations.

    Autoradiographic studies with human cadaverous skin showed that ciclopirox penetrates into the hair and through the epidermis and hair follicles into the sebaceous glands and dermis, while a portion of the drug remains in the stratum corneum.

    Draize Human Sensitization Assay, 21-Day Cumulative Irritancy study, Phototoxicity study, and Photo-Draize study conducted in a total of 142 healthy male subjects showed no contact sensitization of the delayed hypersensitivity type, no irritation, no phototoxicity, and no photo-contact sensitization due to Ciclopirox Olamine Cream.

  • INDICATIONS AND USAGE

    Ciclopirox Olamine Cream USP, 0.77% is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophytonfloccosum, and Microsporum canis; candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur.

  • CONTRAINDICATIONS

    Ciclopirox Olamine Cream USP is contraindicated in individuals who have shown hypersensitivity to any of its components.

  • WARNINGS

    Ciclopirox Olamine Cream USP is not for ophthalmic use.
    Keep out of reach of children.

  • PRECAUTIONS

    If a reaction suggesting sensitivity or chemical irritation should occur with the use of Ciclopirox Olamine Cream, treatment should be discontinued and appropriate therapy instituted.

  • Information for Patients

    The patient should be told to:

    1. Use the medication for the full treatment time even though symptoms may have improved and notify the physician if there is no improvement after four weeks.
    2. Inform the physician if the area of application shows signs of increased irritation (redness, itching, burning, blistering, swelling, or oozing) indicative of possible sensitization.
    3. Avoid the use of occlusive wrappings or dressings.

  • Carcinogenesis, Mutagenesis, Impairment of Fertility

    A 104-week dermal carcinogenicity study in mice was conducted with ciclopirox cream applied at doses up to 1.93% (100 mg/kg/day or 300 mg/m2/day). No increase in drug related neoplasms was noted when compared to control.

    The following in vitro genotoxicity tests have been conducted with ciclopirox: evaluation of gene mutation in the Ames Salmonella and E. coli assays (negative); chromosome aberration assays in V79 Chinese hamster lung fibroblast cells, with and without metabolic activation (positive); chromosome aberration assays in V79 Chinese hamster lung fibroblast cells in the presence of supplemental Fe3+, with and without metabolic activation (negative); gene mutation assays in the HGPRT-test with V79 Chinese hamster lung fibroblast cells (negative); and a primary DNA damage assay (i.e., unscheduled DNA synthesis assay in A549 human cells) (negative). An in vitro cell transformation assay in BALB/c 3T3 cells was negative for cell transformation. In an in vivo Chinese hamster bone marrow cytogenetic assay, ciclopirox was negative for chromosome aberrations at a dosage of 5000 mg/kg body weight.

    A combined oral fertility and embryofetal developmental study was conducted in rats with ciclopirox olamine. No effect on fertility or reproductive performance was noted at the highest dose tested of 3.85 mg/kg/day ciclopirox (approximately 1.2 times the maximum recommended human dose based on body surface area comparisons).

  • Pregnancy

    Teratogenic Effects: Pregnancy Category B

    There are no adequate or well-controlled studies in pregnant women. Therefore, Ciclopirox Olamine Cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

    Oral embryofetal developmental studies were conducted in mice, rats, rabbits and monkeys. Ciclopirox or ciclopirox olamine was orally administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 77, 125, 80 and 38.5 mg/kg/day ciclopirox in mice, rats, rabbits and monkeys, respectively (approximately 11, 37, 51 and 24 times the maximum recommended human dose based on body surface area comparisons, respectively).

    Dermal embryofetal developmental studies were conducted in rats and rabbits with ciclopirox olamine dissolved in PEG 400. Ciclopirox olamine was topically administered during the period of organogenesis. No maternal toxicity, embryotoxicity or teratogenicity were noted at the highest doses of 92 mg/kg/day and 77 mg/kg/day ciclopirox in rats and rabbits, respectively (approximately 27 and 49 times the maximum recommended human dose based on body surface area comparisons, respectively.)

  • Nursing Mothers

    It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Ciclopirox Olamine Cream is administered to a nursing woman.

  • Pediatric Use

    Safety and effectiveness in pediatric patients below the age of 10 years have not been established.

  • ADVERSE REACTIONS

    In all controlled clinical studies with 514 patients using Ciclopirox Olamine Cream and in 296 patients using the vehicle cream, the incidence of adverse reactions was low. This included pruritus at the site of application in one patient and worsening of the clinical signs and symptoms in another patient using ciclopirox cream and burning in one patient and worsening of the clinical signs and symptoms in another patient using the vehicle cream.

    To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc.at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

  • DOSAGE AND ADMINISTRATION

    Gently massage Ciclopirox Olamine Cream USP into the affected and surrounding skin areas twice daily, in the morning and evening. Clinical improvement with relief of pruritis and other symptoms usually occurs within the first week of treatment. If a patient shows no clinical improvement after four weeks of treatment with Ciclopirox Olamine Cream, the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.

  • HOW SUPPLIED

    Ciclopirox Olamine Cream USP, 0.77% is supplied in:

    15-g tubes (NDC 0713-0638-15)
    30-g tubes (NDC 0713-0638-31)
    90-g tubes (NDC 0713-0638-18)

    Store at 20-25°C (68-77°F).
    [See USP Controlled Room Temperature].

    Manufactured by:
    Cosette Pharmaceuticals, Inc. 
    111 Coolidge Street, South Plainfield, NJ 07080 


    8-0638CP1
    Iss. 09/2019

  • PRINCIPAL DISPLAY PANEL

    NDC 0713-0638-15

    Ciclopirox Olamine Cream, USP (Ciclopirox Cream) 0.77%

    15g

    Rx only

    FOR DERMATOLOGIC USE ONLY - NOT FOR USE IN EYES

    Cosette Pharmaceuticals, Inc.

    carton 15g

    tube 15

    NDC 0713-0638-31

    Ciclopirox Olamine Cream, USP (Ciclopirox Cream) 0.77%

    30 g

    Rx only

    FOR DERMATOLOGIC USE ONLY - NOT FOR USE IN EYES

    Cosette Pharmaceuticals, Inc.

    carton 30

    tube 30

    NDC 0713-0638-18

    Ciclopirox Olamine Cream, USP (Ciclopirox Cream) 0.77%

    90 g

    Rx only

    FOR DERMATOLOGIC USE ONLY - NOT FOR USE IN EYES

    Cosette Pharmaceuticals, Inc.

    carton 90

    tube 90

  • INGREDIENTS AND APPEARANCE
    CICLOPIROX OLAMINE  
    ciclopirox olamine cream
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0713-0638
    Route of AdministrationTOPICAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Ciclopirox Olamine (UNII: 50MD4SB4AP) (Ciclopirox - UNII:19W019ZDRJ) Ciclopirox7.7 mg  in 1 g
    Inactive Ingredients
    Ingredient NameStrength
    Cetyl Alcohol (UNII: 936JST6JCN)  
    Mineral Oil (UNII: T5L8T28FGP)  
    Octyldodecanol (UNII: 461N1O614Y)  
    Stearyl Alcohol (UNII: 2KR89I4H1Y)  
    Polysorbate 60 (UNII: CAL22UVI4M)  
    Myristyl Alcohol (UNII: V42034O9PU)  
    Sorbitan Monostearate (UNII: NVZ4I0H58X)  
    Benzyl Alcohol (UNII: LKG8494WBH)  
    Water (UNII: 059QF0KO0R)  
    Lactic Acid (UNII: 33X04XA5AT)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0713-0638-151 in 1 BOX05/22/2007
    115 g in 1 TUBE; Type 0: Not a Combination Product
    2NDC:0713-0638-311 in 1 BOX05/22/2007
    230 g in 1 TUBE; Type 0: Not a Combination Product
    3NDC:0713-0638-181 in 1 BOX05/22/2007
    390 g in 1 TUBE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA07846305/22/2007
    Labeler - Cosette Pharmaceuticals, Inc. (116918230)
    Registrant - Cosette Pharmaceuticals, Inc. (116918230)
    Establishment
    NameAddressID/FEIBusiness Operations
    Cosette Pharmaceuticals, Inc.116918230analysis(0713-0638) , label(0713-0638) , manufacture(0713-0638) , pack(0713-0638)